These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38780771)

  • 1. Sphingosine is involved in PAPTP-induced death of pancreas cancer cells by interfering with mitochondrial functions.
    Patel SH; Wilson GC; Wu Y; Keitsch S; Wilker B; Mattarei A; Ahmad SA; Szabo I; Gulbins E
    J Mol Med (Berl); 2024 Jul; 102(7):947-959. PubMed ID: 38780771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ductal adenocarcinoma cells in vitro and in vivo.
    Patel SH; Bachmann M; Kadow S; Wilson GC; Abdel-Salam MML; Xu K; Keitsch S; Soddemann M; Wilker B; Becker KA; Carpinteiro A; Ahmad SA; Szabo I; Gulbins E
    J Mol Med (Berl); 2023 Mar; 101(3):295-310. PubMed ID: 36790532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancreatic Ductal Adenocarcinoma in an Immunocompetent Orthotopic Murine Model.
    Li W; Wilson GC; Bachmann M; Wang J; Mattarei A; Paradisi C; Edwards MJ; Szabo I; Gulbins E; Ahmad SA; Patel SH
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
    Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
    Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model.
    Severin F; Urbani A; Varanita T; Bachmann M; Azzolini M; Martini V; Pizzi M; Tos APD; Frezzato F; Mattarei A; Ghia P; Bertilaccio MTS; Gulbins E; Paradisi C; Zoratti M; Semenzato GC; Leanza L; Trentin L; Szabò I
    J Exp Clin Cancer Res; 2022 Feb; 41(1):64. PubMed ID: 35172855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
    Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA
    Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo.
    Leanza L; Romio M; Becker KA; Azzolini M; Trentin L; Managò A; Venturini E; Zaccagnino A; Mattarei A; Carraretto L; Urbani A; Kadow S; Biasutto L; Martini V; Severin F; Peruzzo R; Trimarco V; Egberts JH; Hauser C; Visentin A; Semenzato G; Kalthoff H; Zoratti M; Gulbins E; Paradisi C; Szabo I
    Cancer Cell; 2017 Apr; 31(4):516-531.e10. PubMed ID: 28399409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines.
    Leanza L; O'Reilly P; Doyle A; Venturini E; Zoratti M; Szegezdi E; Szabo I
    Curr Pharm Des; 2014; 20(2):189-200. PubMed ID: 23701546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting KRAS in pancreatic cancer.
    Stickler S; Rath B; Hamilton G
    Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
    Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
    Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
    Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
    Zhang S; Chung WC; Xu K
    Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future.
    Li C; Yin X; Liu Z; Wang J
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
    Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
    Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.